Trial Profile
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs FAZ 053 (Primary) ; Spartalizumab (Primary)
- Indications Advanced breast cancer; Alveolar soft part sarcoma; Carcinoma; Chordoma; Penile cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Novartis Pharmaceuticals
- 02 Feb 2024 Planned End Date changed from 14 Jun 2024 to 14 Nov 2024.
- 02 Feb 2024 Planned primary completion date changed from 14 Jun 2024 to 14 Nov 2024.
- 28 Jul 2022 Planned End Date changed from 23 Mar 2023 to 14 Jun 2024.